Stock Events

Stock Events

Crinetics Pharmaceuticals 

$84.95
20
+$0.10+0.12% Monday 20:00
+$0.03+0.03%Monday 23:49After hours

Statistics

Day High
85.01
Day Low
84.92
52W High
85.01
52W Low
31
Volume
8,182,078
Avg. Volume
4,095,514
Mkt Cap
9.01B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

17NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-1.38
-1.21
-1.05
-0.88
Expected EPS
-1.152321
Actual EPS
N/A

Financials

-6,046.22%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
7.7MRevenue
-465.32MNet Income

Analyst Ratings

86.13Average Price Target
The highest estimate is 95.00.
From 10 ratings within the last 6 months. This is not an investment recommendation.
Buy
20%
Hold
80%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CRNX. It's not an investment recommendation.
Apple
6
AAPL
Amazon
6
AMZN
NVIDIA
6
NVDA
AMD
6
AMD

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Ipsen
IPSEY
Mkt Cap15.77B
Ipsen operates in the endocrinology market, directly competing with Crinetics Pharmaceuticals' focus on endocrine diseases and tumors.
Pfizer
PFE
Mkt Cap159.36B
Pfizer has a broad portfolio that includes treatments for endocrine disorders, competing in the same therapeutic areas as Crinetics.
Novo Nordisk
NVO
Mkt Cap201.64B
Novo Nordisk specializes in hormone replacement therapies and treatments for endocrine diseases, overlapping with Crinetics' market.
Lilly(Eli) &
LLY
Mkt Cap1.05T
Eli Lilly has a strong presence in the endocrinology market, including treatments for conditions that Crinetics Pharmaceuticals targets.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca has a diverse portfolio that includes endocrine and metabolic disease treatments, competing with Crinetics Pharmaceuticals.
Merck
MRK
Mkt Cap366B
Merck operates in various therapeutic areas, including endocrinology, directly competing with Crinetics Pharmaceuticals' focus areas.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie has a significant presence in the endocrine market, with treatments that compete against Crinetics Pharmaceuticals' products.
Sanofi
SNY
Mkt Cap107.39B
Sanofi has a broad range of treatments for endocrine disorders, directly competing with Crinetics Pharmaceuticals.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap42.46B
Teva Pharmaceutical Industries offers generic and specialty medicines, including treatments for endocrine disorders, competing with Crinetics.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals focuses on innovative treatments, including for endocrine disorders, potentially competing with Crinetics Pharmaceuticals' pipeline.

About

Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
Show more...
CEO
R. Scott Struthers
Employees
594
Country
United States
ISIN
US22663K1079
WKN
000A2JQTJ

Listings

MU
DE
6Z4.MU
STU
DE
6Z4.STU
BOATS
BOATS
CRNX.BOATS
F
DE
6Z4.F

0 Comments

Share your thoughts

FAQ

What is Crinetics Pharmaceuticals stock price today?▼
The current price of CRNX is $84.95 USD — it has increased by +0.12% in the past 24 hours. Watch Crinetics Pharmaceuticals stock price performance more closely on the chart.
What is Crinetics Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Crinetics Pharmaceuticals stocks are traded under the ticker CRNX.
Is Crinetics Pharmaceuticals stock price growing?▼
CRNX stock has risen by +0.13% compared to the previous week, the month change is a +1.71% rise, over the last year Crinetics Pharmaceuticals has showed a +155.11% increase.
What is Crinetics Pharmaceuticals market cap?▼
Today Crinetics Pharmaceuticals has the market capitalization of 9.01B
When is the next Crinetics Pharmaceuticals earnings date?▼
Crinetics Pharmaceuticals is going to release the next earnings report on November 17, 2026.
What were Crinetics Pharmaceuticals earnings last quarter?▼
CRNX earnings for the last quarter are -1.14 USD per share, whereas the estimation was -1.18 USD resulting in a +3.28% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Crinetics Pharmaceuticals revenue for the last year?▼
Crinetics Pharmaceuticals revenue for the last year amounts to 7.7M USD.
What is Crinetics Pharmaceuticals net income for the last year?▼
CRNX net income for the last year is -465.32M USD.
How many employees does Crinetics Pharmaceuticals have?▼
As of September 02, 2026, the company has 594 employees.
In which sector is Crinetics Pharmaceuticals located?▼
Crinetics Pharmaceuticals operates in the Health & Wellness sector.
When did Crinetics Pharmaceuticals complete a stock split?▼
Crinetics Pharmaceuticals has not had any recent stock splits.
Where is Crinetics Pharmaceuticals headquartered?▼
Crinetics Pharmaceuticals is headquartered in SAN DIEGO, United States.